stockrowAscendis Pharma A/S
ASND Healthcare Biotechnology
Ascendis Pharma A/S’s revenue for fiscal 2025 (year ended December 2025) was $814.8 million, up 107.1% from fiscal 2024.
- Revenue
- +119.9%
- EPS
- +612.3%
- Free cash flow
- +2,335.9%
- Total debt
- −41.8%
Quarter to June 2026, against a year earlier
Follow ASND
Alert me
Ascendis Pharma A/S (ASND) Return on equity
Ascendis Pharma A/S's return on equity over the twelve months to 30 June 2026 was 118.4%, down 54.4 percentage points from fiscal 2025 (172.8%). Over the past ten years it has ranged from −870.1% (fiscal 2023) to 300.8% (fiscal 2024); the current reading is higher than 91% of that period. That is above the Biotechnology industry median of −50.1% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 172.8% | (127.95) |
| FY2024 | 300.8% | 1,170.83 |
| FY2023 | −870.1% | (777.18) |
| FY2022 | −92.9% | (47.60) |
| FY2021 | −45.3% | 13.54 |
| FY2020 | −58.8% | (9.98) |
| FY2019 | −48.9% | 7.80 |
| FY2018 | −56.7% | 12.15 |
| FY2017 | −68.8% | (22.73) |
| FY2016 | −46.1% | (8.49) |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| HALO Halozyme Therapeutics, Inc. compare | 216.4% |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 138.1% |
| ASND Ascendis Pharma A/S | 118.4% |
| EXEL Exelixis, Inc. compare | 44.3% |
| BBIO BridgeBio Pharma, Inc. compare | 26.2% |
| JAZZ Jazz Pharmaceuticals PLC compare | 5.05% |
| BNTX BioNTech SE Sponsored ADR compare | −8.29% |
| INSM Insmed, Inc. compare | −72.5% |
| SMMT Summit Therapeutics PLC compare | −192.5% |
| Biotechnology industry median | −50.1% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on ASND
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement